Pulmonary valve replacement—A 10-year single-center surgical experience in ACHD patients
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0310700 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Armin Darius Peivandi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, University Hospital Muenster, Muenster, Germany. Hauptthemen laut MEDLINE: Pulmonary Valve, Heart Valve Prosthesis Implantation, Heart Defects, Congenital. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Large-scale analyses of surgical outcomes after surgical pulmonary valve replacement (sPVR) as part of re-do surgery in adults with congenital heart disease (ACHD) are rare. Therefore, we present our outcomes of sPVR in ACHD patients over the last decade and demonstrate our standardized surgical approach. All ACHD patients who underwent sPVR between January 2013 and August 2022 were included. Primary diagnoses, peri-operative data, post-operative echocardiography, pre- and post-operative RV MRI and in-hospital mortality were examined. Pre- and postoperative MRI parameters were compared using paired testing. Standardized surgery was documented. Normality of continuous variables was tested using Shapiro-Wilk test. 79 patients (male 59.5% (n = 47), 71 re-operations (89.9%)) at a median age of 41.7 (52.2–28.8) years were included. Main underlying disease was Tetralogy of Fallot (TOF; n = 47, 59.5%). After removal of degenerated valve/conduit parts, right ventricular outflow tract (RVOT) patch augmentation and implantation of a larger stented bioprosthesis (25mm in 78.5%) were conducted. In 57% of cases, concomitant surgery was performed (mainly tricuspid valve surgery: n = 28, 35.4%). 25 patients (31.6%) were operated with beating heart technique. Echocardiographic outcomes showed no moderate or severe insufficiency (median V max of 2 m/s (2.3–1.77 m/s)) upon discharge. Available MRI data showed significantly lower indexed RV-EDV (p = 0.0006) and RV-ESV (P = 0.0017) after surgery. In-hospital mortality was 5.1% (n = 4). SPVR is a safe therapeutic option with low surgical risk and satisfying post-operative results. It can serve as a solid therapeutic option for patients who need future valve-in-valve interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, University Hospital Muenster, Muenster, Germany.
ORCID-Profile: Armin Darius Peivandi, Andreas Rukosujew, Sabrina Martens
Zitieren
APA
Peivandi, A. D., Martens, S., Gion, A., Rukosujew, A., & Martens, S. (2024). Pulmonary valve replacement—A 10-year single-center surgical experience in ACHD patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0310700
Vancouver
Peivandi AD, Martens S, Gion A, Rukosujew A, Martens S. Pulmonary valve replacement—A 10-year single-center surgical experience in ACHD patients. PLOS ONE. 2024. doi:10.1371/journal.pone.0310700
BibTeX
@article{Peivandi2024,
author = {Peivandi, Armin Darius and Martens, Sven and Gion, Anaïs and Rukosujew, Andreas and Martens, Sabrina},
title = {Pulmonary valve replacement—A 10-year single-center surgical experience in ACHD patients},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0310700}
}
EUVIMED